The Global Landscape of Broad-Spectrum Antiviral Therapeutics: Strategic Evolution, Mechanism of Action, and Comparative Efficacy in 2026

The pharmaceutical landscape for infectious diseases has undergone a radical transformation by 2026, shifting from a reactive "one-drug-one-bug" paradigm toward a proactive, platform-based approach centered on broad-spectrum antivirals (BSAs).[1] This evolution is driven by the increasing frequency of zoonotic spillovers, the persistence of seasonal "tripledemics" involving influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, and the strategic necessity of pandemic preparedness.[3] Market projections indicate that by 2026, the broad-spectrum segment will command a 48.0% share of the zoonotic antiviral market, reflecting an urgent prioritization by government stockpiles and public health agencies for agents that can be deployed against novel or unknown pathogens before strain-specific countermeasures are developed.[1]

The Strategic Imperative: Transitioning from Specificity to Pan-Viral Breadth

The traditional approach to antiviral development, while successful for chronic infections such as HIV and Hepatitis C, proved inadequate during the rapid onset of the COVID-19 pandemic.[5] The time required to develop, test, and distribute strain-specific treatments leaves human populations vulnerable during the critical early phases of an outbreak.[1] Consequently, the 2026 antiviral market is increasingly defined by "platform technologies" capable of generating adaptable candidates that target conserved viral mechanisms or host-side pathways.[1] Investment is heavily focused on direct-acting, broad-spectrum antivirals that target conserved domains within viral families, such as RNA-dependent RNA polymerases (RdRp), or host-mimetic decoys that prevent viral entry.[2] This shift is exemplified by the emergence of "basket trials"—clinical designs that allow a single drug to be tested across multiple viral infections simultaneously—an approach championed by global health experts as the only efficient method to solve multi-viral crises.[3]

Economic Foundations and Market Dynamics in 2026

The global market for antiviral drugs is estimated to reach USD 70.73 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.5%.[12] Within this broader market, the zoonotic

antiviral segment is projected to grow from USD 2.49 billion in 2026 to USD 5.97 billion by 2036, reflecting the escalating threat of animal-to-human virus transmission.[1]

Market Metric (2026 Forecast)	Value (USD)	Regional / Segment Lead
Global Antiviral Drugs Market	USD 70.73 Billion	North America (39.7% share) [12]
Zoonotic Antivirals Market	USD 2.49 Billion	Emerging Zoonoses (56.0% share) [1]
U.S. Antiviral Market Size	USD 25.79 Billion	Branded Drugs (55.3% share) [7]
Zoonotic Broad-Spectrum Share	48.0%	Government Stockpiles (46.0% share) [1]
Influenza Antiviral Market	USD 1.147 Billion	Neuraminidase Inhibitors [13]

The dominance of North America is attributed to high healthcare expenditure and the presence of leading biopharmaceutical firms investing in next-generation antivirals with lower resistance rates.[12] Furthermore, the strategic stockpiling by governments for pandemic preparedness has created a stable procurement demand for broad-spectrum assets capable of countering diverse RNA viruses.[1]

Comparative Landscape of Best Available Antiviral Drugs

As of early 2026, the clinical standard for viral infections is divided between established, highly effective "cures" for chronic conditions and emerging broad-spectrum agents for acute respiratory and tropical diseases.

Current Clinical Standards for Major Viral Indications (2026)

Condition	Best Available Drug / Regimen (2026)	Clinical Significance and Notes
Dengue Fever	**XAFTY (CP-COV03)**	Undergoing Phase 2/3 trials in Vietnam; MoU between Hyundai Bio and DNDi for global deployment.[3]
Seasonal Flu	**Xofluza (Baloxavir Marboxil)**	Single-dose oral treatment; superior to Tamiflu in reducing viral load; inhibits cap-dependent endonuclease.[15]
COVID-19	**Paxlovid**	Best for high-risk/early-stage;

	(Nirmatrelvir/Ritonavir)	3CL protease inhibition remains standard for preventing hospitalization.[10]
Hepatitis B / C	**Tenofovir / Sofosbuvir**	Highly successful regimens; achieve viral suppression (HBV) or functional cures (HCV) exceeding 95%.[16]
GI Viruses	**Nitazoxanide (NTZ)**	FDA-approved; off-label broad-spectrum use for Norovirus, Rotavirus, and Giardia.[18]
Mpox / Orthopox	**NV-387**	Emerging lead; Phase 2 trials in DRC; targets clades Ia and Ib; superior potential where TPOXX failed.[20]

While these drugs represent the "Best Available" in their respective categories, the landscape is shifting toward candidates with even broader efficacy, capable of treating multiple families with a single formulation.

Investigating the Spectrum: Ranking the Broadest Antiviral Candidates

The primary objective of the 2026 landscape analysis is to identify agents with the maximum possible breadth of action. This ranking is based on a combination of theoretical mechanism, validated preclinical data, and clinical progress.

Ranking of Antivirals by Broadest Efficacy (2026 Landscape)

Rank	Candidate	Mechanism of Action	Breadth of Efficacy (Target Viruses/Families)	Status (2026)
1	**NV-387**	Host-Mimetic (HSPG Decoy)	**Extremely Broad**: Coronaviruses, RSV, Influenza (A/B, H5N1), Poxviruses (Mpox, Smallpox), Measles, Filoviruses (Ebola), Paramyxoviruses.[9]	Phase 2 (DRC/India); targets >90% of pathogenic viruses.[9]

2	**MDL-001**	RdRp Thumb-1 Allosteric Inhibitor	**Very Broad**: HCV, HBV, HDV, SARS-CoV-2, Influenza A/B, RSV, Norovirus.[10]	IND-enabling studies complete; targeted clinical trials early 2027.[25]
3	**Nitazoxanide**	Thiazolide (Host & Viral modulation)	**Broad**: Norovirus, Rotavirus, RSV, Flu, COVID-19, Dengue, HBV, HCV, Yellow Fever.[18]	FDA-approved; repurposed for acute respiratory and hepatic infections.[18]
4	**XAFTY (CP-COV03)**	Niclosamide (Autophagy Modulator)	**Multi-Family**: SARS-CoV-2, Influenza, RSV, Dengue, Mpox.[3]	Phase 2 (US/Vietnam); "One Drug, Two Tracks" clinical strategy.[3]
5	**Remdesivir**	RdRp Nucleotide Analog (Chain Terminator)	**RNA Families**: Coronaviruses (SARS/MERS/COVID), Filoviruses (Ebola), Paramyxoviruses (RSV).[28]	FDA-approved; standard of care for hospitalized COVID patients.[28]
6	**Molnupiravir**	RdRp Nucleoside Analog (Lethal Mutagenesis)	**RNA Families**: Coronaviruses, Influenza, RSV, Alpha-viruses (VEEV).[31]	FDA-authorized; oral bioavailability makes it a primary BSA for outpatient use.[30]
7	**Bemnifosbuvir**	Guanosine Nucleotide Prodrug (RdRp)	**Hepatic & Tropical**: HCV, HEV, Flaviviruses (Dengue), Rubella, Chikungunya.[34]	Phase 3 (HCV); high potency vs standard of care.[35]
8	**NV-287**	Pyridopyrazine (Kinase Modulator)	**Niche Broad-Spectrum**: RNA Viruses, HIV, pathological cell proliferation.[38]	Early discovery / Patent stage; listed as anti-infective/antiviral.[38]

The "Broadest" Contender: NV-387 and Host-Mimetic Nanotechnology

The most expansive claim to broad-spectrum efficacy in 2026 comes from NanoViricides, Inc., with their lead candidate, NV-387. The drug represents a departure from direct-acting antivirals that target specific viral enzymes, which are prone to mutation and resistance.[9]

Mechanism of Action: The HSPG Decoy Strategy

NV-387 utilizes a unique "host-mimetic" platform designed to exploit a conserved biological fact: over 90% of human pathogenic viruses utilize Heparan Sulfate Proteoglycans (HSPG) or related sulfated proteoglycans (S-PG) as an initial attachment point to infect human cells.[9] NV-387 is engineered as a nano-polymer micelle that presents copious amounts of these binding sites to the virus, essentially acting as a decoy reservoir.[9]
The mechanism involves two primary stages:

1. **Attachment**: The virus particle, "fooled" by the host-like binding domains on the NV-387 nanomicelle, attaches to the drug instead of the host cell.[22]
2. **Destruction**: The nanomicelle destabilizes the virus particle. Because the virus requires HSPG for entry, it cannot easily evolve to avoid this decoy without losing its ability to infect human cells, making resistance highly unlikely.[9]

Preclinical and Clinical Validation (2025-2026)

Lethal animal models conducted through 2025 have demonstrated that NV-387 is significantly superior to existing standards for several major threats:

- **Influenza**: In mouse models of lethal H3N2 lung infection, NV-387 was found to be substantially superior to both oseltamivir (Tamiflu) and baloxavir (Xofluza).[9]
- **RSV**: In comparative studies, NV-387 completely protected mice from death and prevented the formation of lung damage, outperforming ribavirin, which has a known profile of hematological and nephrological toxicity.[9]
- **Mpox**: NV-387 matched the activity of tecovirimat (TPOXX) in increasing survival by 75% in skin-abrasion models of Mpox, while combination therapy (NV-387 + TPOXX) led to a 138% increase in survival.[22]
- **Measles**: Tested in humanized CD150 mice, NV-387 increased survival to an average of 17 days compared to 7.4 days in untreated animals.[22]

The current clinical strategy for NV-387 involves a dual-track approach. The first trial targets Mpox in the Democratic Republic of Congo (DRC) to address the urgent WHO-declared public health emergency.[20] The second trial is an adaptive "basket-type" study planned for 2026 in India, designed to evaluate NV-387 efficacy against the respiratory "tripledemic" of flu, RSV, and coronaviruses.[22] Success in these trials would enable NV-387 to become the first antiviral prescribed by physicians based on symptoms alone (empiric therapy), without waiting for specific viral testing.[9]

AI-Native Innovation: MDL-001 and the RdRp Thumb-1 Domain

A major breakthrough in the 2026 landscape is the identification of the Thumb-1 domain as a conserved allosteric target across multiple viral families, a discovery enabled by the AI-native biotechnology company Model Medicines.[10]

Exploiting the Thumb-1 Allosteric Domain

The viral RNA-dependent RNA polymerase (RdRp) is essential for the replication of most RNA viruses. While the active sites of these polymerases can vary significantly, structural analysis and machine-learning bioactivity screens (processing up to 325 billion compounds) identified the Thumb-1 domain as a highly conserved site.[24] MDL-001 is a first-in-class, oral, direct-acting, non-nucleoside antiviral that targets this domain.[10]

Pathogen Family	Target Virus	MDL-001 Preclinical Result
Flaviviridae	Hepatitis C (HCV)	3.1-log_{10} reduction in viral load; equivalent to sofosbuvir.[10]
Hepadnaviridae	Hepatitis B (HBV)	1.8-log_{10} reduction; first single-agent therapy to suppress both HBV and HCV.[10]
Coronaviridae	SARS-CoV-2	Non-inferior to subcutaneous remdesivir; superior to nirmatrelvir (Paxlovid).[10]
Orthomyxoviridae	Influenza A/B	Submicromolar potency; favorable lung tissue accumulation exceeding EC_{90}.[10]
Pneumoviridae	RSV	Potent suppression; high selectivity index relative to standard care.[10]

Clinical Differentiation and Addressing Co-Infection

The clinical significance of MDL-001 lies in its ability to treat patients with viral co-infections, a population currently underserved.[16] In HCV/HBV co-infected patients, current direct-acting antivirals for HCV can cause HBV reactivation, necessitating complex treatment regimens. MDL-001's ability to suppress both viruses with a single oral agent simplifies the treatment paradigm and reduces liver cancer risk, which is 100 times higher in co-infected individuals.[16] Pharmacokinetic (PK) studies have confirmed that MDL-001 achieves clinically meaningful viral load reductions with a safety profile validated in over 400 animals.[10] The company is completing IND-enabling studies in late 2026, with clinical trial initiation anticipated in early 2027.[25]

Repurposing and Advanced Drug Delivery: XAFTY

(CP-COV03)

The 2026 landscape also features XAFTY, an oral broad-spectrum candidate that illustrates the potential of re-engineering well-known molecules for broader application.[3]

Niclosamide Re-engineering

XAFTY is based on niclosamide, a compound with long-established broad-spectrum antiviral properties that were previously hindered by poor oral absorption and a short half-life.[3] Hyundai Bioscience successfully reformulated niclosamide using a proprietary organic-inorganic hybrid drug delivery system to enhance bioavailability and achieve therapeutic plasma levels.[5]
The mechanism of action is primarily host-directed, involving the modulation of autophagy to inhibit viral replication across diverse families.[3] Unlike direct-acting antivirals that target viral proteins, this approach makes XAFTY less susceptible to variants and mutations.[3]

The "One Drug, Two Tracks" Global Strategy

Hyundai Bioscience has adopted a parallel clinical development roadmap to address divergent public health threats:

- **Track 1: Tropical Viruses (Vietnam)**: XAFTY is being developed as the first specific treatment for Dengue fever. Following an MOU with the Drugs for Neglected Diseases initiative (DNDi), the drug is entering Phase 2/3 trials in Vietnam to provide an affordable treatment option for low- and middle-income countries.[3]
- **Track 2: Respiratory Viruses (United States)**: The drug is entering Phase 2 trials in the U.S., endorsed by experts such as Dr. Davey Smith (former ACTIV-2 Protocol Chair), as a "weapon to end the virus war".[3] The U.S. program utilizes a basket trial design to target the "tripledemic" of influenza, RSV, and COVID-19 variants.[3]

Animal studies have shown that XAFTY considerably reduces influenza virus levels compared to oseltamivir (Tamiflu), proving its in vivo efficacy across different respiratory virus families.[5]

The Role of NV-287 and the Kinase Modulator Landscape

Among the broader landscape of candidates, NV-287 is identified as a novel pyrido[2,3-b]pyrazine derivative.[38] This class of drugs functions as modulators of kinases, enzymes critical for cellular signaling pathways that viruses often hijack for their replication and assembly.[38]

Efficacy and Applications of Pyridopyrazines

The patent landscape for NV-287 and its analogs (formulas I and II) indicates activity across a range of disorders, including:

- **RNA Viruses**: Specifically listed for the treatment of RNA viral disorders, including HIV.[38]

- **Host-Directed Effects**: Kinase modulation can affect cell-side features such as pathological cell proliferation and inflammatory responses.[38]
- **Respiratory and Systemic Disorders**: The class is also investigated for disorders of the respiratory system, skeletal disorders, and as an immunomodulator.[39]

While NV-387 and MDL-001 have reached the clinical stage for acute viral threats, NV-287 represents an earlier-stage, highly specialized approach to broad-spectrum efficacy through the disruption of host-cell signaling necessary for the viral life cycle.[38]

Established Mechanisms and Synergistic Combinations

Direct-acting antivirals like remdesivir and molnupiravir, which emerged during the pandemic, remain core components of the 2026 landscape, particularly in combination therapies designed to prevent resistance.

Comparative Mechanisms of Direct-Acting Antivirals (DAAs)

Drug	Mechanism	Spectrum Highlight	Key Limitation
Remdesivir	Delayed chain termination via RdRp inhibition.[28]	Highly potent vs Coronaviruses and Filoviruses (Ebola).[29]	Primary administration is intravenous, limiting outpatient use.[30]
Molnupiravir	Lethal mutagenesis (error catastrophe) in viral genome.[31]	Broad RNA virus activity; oral bioavailability.[32]	Lower clinical efficacy in some trials compared to protease inhibitors.[31]
Paxlovid	3CL Protease inhibition (specifically targeting viral polyprotein cleavage).[10]	High efficacy in early-stage COVID-19.[16]	Significant drug-drug interactions (DDI) due to the ritonavir component.[10]

Triple Combination Therapy: A 2026 Breakthrough

Recent research published in 2024 and 2026 has identified that a "triple combination" of remdesivir ($GS\text{-}441524$), molnupiravir, and ribavirin is highly efficient in inhibiting coronavirus replication.[32] In Syrian hamster models, this combination resulted in no detectable infectious virus in the lungs, a level of clearance not achieved by monotherapy.[32] This suggests that targeting the viral RdRp through multiple pathways—chain termination, error induction, and nucleoside analog competition—provides a more resilient and potent therapeutic effect.[32]

Nitazoxanide: The Prototypical Broad-Spectrum

Thiazolide

Nitazoxanide (NTZ) continues to be a high-interest molecule in 2026 for its established safety and multifaceted mechanism.[18] As the prototype of the thiazolides, NTZ is an antiprotozoal drug that exhibits potent broad-spectrum antiviral activity through host-directed mechanisms.[18]

- **Antiviral Efficacy**: NTZ inhibits the viral replication phase of various viruses, including swine viruses (PRRSV), influenza, and coronaviruses, without causing significant cytotoxicity to host cells.[19]
- **Cytokine Modulation**: A "special quality" of NTZ is its ability to promote balance between pro-inflammatory and anti-inflammatory mediators (e.g., reduction in IL-6), which is potentially helpful in managing the cytokine storms associated with severe viral infections.[18]
- **Pharmacokinetics and Bioavailability**: NTZ's exposure (AUC) can be increased by 45-50% when administered with food, though its suspension form has 30% lower bioavailability than tablets.[18]

NTZ Target Area	Specific Pathogen / Result	Clinical Status
Respiratory	RSV, Parainfluenza, Coronaviruses	Investigated for repurposing; reduces COVID viral load by $\ge 35\%$ in 7 days.[18]
Hepatic	HBV, HCV	Investigated as potential adjunct treatment.[18]
Tropical	Dengue (DENV), Yellow Fever (YFV)	Demonstrated in vitro efficacy.[18]
Swine Viruses	PRRSV, PEDV	Marked suppression in dose-dependent manner.[27]

Strategic Preparedness: Host-Directed and Broad-Spectrum R&D

The discovery of broad-spectrum, host-directed antivirals is critical for preparing for future pandemics.[8] In 2026, research increasingly focuses on pathways that support viral entry, replication, and assembly, as these are less prone to the rapid mutations seen in viral enzymes.[8]

Host Pathways as Antiviral Targets (2026 Review)

- **DHODH (Dihydroorotate Dehydrogenase)**: Inhibitors such as "Compound 11" have emerged as potent broad-spectrum agents by depleting the pyrimidine pools essential for viral replication.[45] This approach has shown superior activity against H1N1 and SARS-CoV-2 compared to traditional inhibitors like Teriflunomide.[45]
- **TMPRSS2 (Transmembrane Protease Serine 2)**: This host protease is critical for the

entry of many respiratory viruses. Serine endopeptidase inhibitors targeting TMPRSS2 have demonstrated broad-spectrum efficacy against SARS-CoV-2 variants (e.g., JN.1) and influenza A (H1N1) in animal models.[47]

- **Autophagy and Cathepsins**: Host-directed strategies using protease inhibitors like saquinavir have been repurposed to enhance the proteolytic activity of cathepsins in macrophages, facilitating the clearance of both intracellular pathogens (like Mtb) and viruses.[48]

Target Mechanism	Candidate / Drug	Breadth Metric
Pyrimidine Synthesis (DHODH)	Compound 11	$IC_{50} = 0.85\text{ }\mu\text{M}$ (H1N1); $3.6\text{ }\mu\text{M}$ (SARS-CoV-2).[45]
Host Entry Protease (TMPRSS2)	Serine Endopeptidase Inhibitors	Effective across Coronaviridae and Orthomyxoviridae.[47]
Transcription (BRD4)	MDL-4102	AI-discovered; targets transcriptional regulators in oncology and virology.[26]

Conclusions and Strategic Outlook

The analysis of the 2026 broad-spectrum antiviral landscape reveals a decisive shift toward platforms that offer multi-family protection and empiric treatment potential.

1. **Broadest Efficacy Leader**: **NV-387** stands as the broadest spectrum candidate due to its host-mimetic decoy mechanism, which theoretical analysis and preclinical data suggest can capture >90% of human pathogenic viruses by mimicking the HSPG receptor.[9] Its success in Phase 2 trials for Mpox and ARI/SARI will be the primary value inflection point for the segment.[21]
2. **AI-Driven Precision**: **MDL-001** represents the most advanced direct-acting broad-spectrum agent, utilizing the newly identified RdRp Thumb-1 domain to achieve high-potency suppression across six viral families, including a unique dual-suppression of HBV and HCV.[10]
3. **Global Repurposing Strategy**: **XAFTY** serves as the clinical vanguard for repurposed broad-spectrum therapeutics, utilizing advanced drug delivery to address both endemic tropical diseases (Dengue) and seasonal respiratory epidemics through a unified oral formulation.[3]
4. **Established Standards and Combinations**: While **Xofluza**, **Paxlovid**, and **Sofosbuvir** remain the "Best Available" for specific indications, the move toward "Triple Combinations" (e.g., Remdesivir/Molnupiravir/Ribavirin) reflects a new standard for clinical preparedness to mitigate drug resistance and maximize viral clearance.[15]
5. **Market Outlook**: With nearly 50% of the zoonotic market dominated by broad-spectrum assets, and government stockpiles serving as the primary end-user, the development of these multi-virus weapons is no longer merely a clinical pursuit but a foundational pillar of

global health security and biodefense.[1]

The year 2026 marks the inaugural year of modern treatments capable of addressing multiple viruses with a single drug, potentially including pathogens that have yet to emerge from the zoonotic reservoir.[3] The integration of AI, nanomedicine, and host-directed pharmacology provides a resilient framework for a future where viral outbreaks are managed with pre-emptive, unified countermeasures rather than reactive, strain-specific interventions.[2]

Works cited

1. Zoonotic Antivirals Market | Global Industry Analysis & Outlook - 2036, accessed March 19, 2026, https://www.factmr.com/report/zoonotic-antivirals-market
2. Article: Redefining ID&V Clinical Development: Key Trends and Innovations Shaping 2026 and Beyond - Medpace, accessed March 19, 2026, https://www.medpace.com/wp-content/uploads/2025/12/Article-Redefining-IDV-Clinical-Development-Key-Trends-and-Innovations-Shaping-2026-and-Beyond.pdf
3. Hyundai Bioscience Unveils Broad-Spectrum Antiviral Strategy as It Enters US Phase 2 Trials - Clival Database, accessed March 19, 2026, https://clival.com/news/hyundai-bioscience-unveils-broad-spectrum-antiviral-strategy-as-it-enters-us-phase-2-trials
4. Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus - Barchart.com, accessed March 19, 2026, https://www.barchart.com/story/news/37051910/hyundai-bioscience-confirms-entry-into-u-s-fda-phase-2-trials-for-broad-spectrum-antiviral-xafty-following-2026-biotech-showcase-consensus
5. Hyundai Bioscience announces XAFTY, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue - FirstWord Pharma, accessed March 19, 2026, https://firstwordpharma.com/story/5894187
6. Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics - ResearchGate, accessed March 19, 2026, https://www.researchgate.net/publication/399769789_Strategic_Preparedness_of_Broad-Spectrum_Antivirals_for_Rapid_Response_Towards_Next_Pandemics
7. US Antiviral Drugs Market Size and Growth 2026 to 2035 - Nova One Advisor, accessed March 19, 2026, https://www.novaoneadvisor.com/report/us-antiviral-drugs-market
8. Recent Advances in Anti-HCV, Anti-HBV and Anti-Flavivirus Agents - PMC, accessed March 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12846337/
9. NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 - FirstWord Pharma, accessed March 19, 2026, https://firstwordpharma.com/story/7062847
10. Model Medicines To Present Preclinical Data Readout for MDL-001, a Direct-Acting, Broad-Spectrum Antiviral Targeting a Novel Viral Mechanism, at IDWeek™ 2025 - BioSpace, accessed March 19, 2026, https://www.biospace.com/press-releases/model-medicines-to-present-preclinic

al-data-readout-for-mdl-001-a-direct-acting-broad-spectrum-antiviral-targeting-a-novel-viral-mechanism-at-idweek-2025
11. Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus - BioSpace, accessed March 19, 2026, https://www.biospace.com/press-releases/hyundai-bioscience-confirms-entry-into-u-s-fda-phase-2-trials-for-broad-spectrum-antiviral-xafty-following-2026-biotech-showcase-consensus
12. Antiviral Drugs Market Share and Opportunities, 2026-2033 - Coherent Market Insights, accessed March 19, 2026, https://www.coherentmarketinsights.com/market-insight/antiviral-drugs-market-4912
13. Strategic Trends in influenza antiviral drugs Market 2026-2034, accessed March 19, 2026, https://www.datainsightsmarket.com/reports/influenza-antiviral-drugs-1491214
14. Hyundai Bio (HDB) and DNDi sign MOU for joint development of Xafty-based dengue treatment |, accessed March 19, 2026, https://dndi.org/press-releases/2025/hyundai-bio-and-dndi-sign-mou-for-potential-dengue-treatment/
15. Influenza Antiviral Medications: Summary for Clinicians - CDC, accessed March 19, 2026, https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html
16. Preclinical data for MDL-001 indicates potential across multiple viral infections, accessed March 19, 2026, https://www.clinicaltrialsarena.com/analyst-comment/preclinical-data-mdl-001-viral-infections/
17. Model Medicines Demonstrates First Single-Agent Antiviral Active Against Both Hepatitis C & Hepatitis B, accessed March 19, 2026, https://modelmedicines.com/newsroom/model-medicines-demonstrates-first-single-agent-antiviral-active-against-both-hepatitis-c-and-hepatitis-b
18. Nitazoxanide – Knowledge and References - Taylor & Francis, accessed March 19, 2026, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Nitazoxanide/
19. Efficacy of Nitazoxanide in reducing the viral ad in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. | Medical Research Archives - European Society of Medicine, accessed March 19, 2026, https://esmed.org/MRA/mra/article/view/3364
20. Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical ..., accessed March 19, 2026, https://www.biospace.com/press-releases/broad-spectrum-antiviral-drug-nv-387-cleared-for-phase-ii-clinical-trial-application-by-the-national-ethics-committee-of-the-democratic-republic-of-congo
21. Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency, accessed March 19, 2026, https://globalbiodefense.com/2025/07/17/mpox-nv387-drug-trial-who-emergenc

y-2025/
22. NNVC: Getting Set for Phase 2 Trial of NV-387 in MPox... - Zacks Small Cap Research, accessed March 19, 2026, https://scr.zacks.com/news/news-details/2025/NNVC-Getting-Set-for-Phase-2-Trial-of-NV-387-in-MPox-article/default.aspx
23. NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value - FirstWord Pharma, accessed March 19, 2026, https://firstwordpharma.com/story/5983228
24. 232. MDL-001: A Broad-Spectrum Antiviral Targeting the Thumb-1 Domain of Viral Polymerases - PMC, accessed March 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12793350/
25. Model Medicines - BIO Investment & Growth Summit 2026, accessed March 19, 2026, https://bigs.bio.org/program-testing/model-medicines
26. Model Medicines to Highlight Two IND-Track Assets, Record-Setting AI Platform at BIO Investment & Growth Summit 2026, accessed March 19, 2026, https://modelmedicines.com/newsroom/model-medicines-to-highlight-two-ind-track-assets-record-setting-ai-platform-at-bio-investment-growth-summit-2026
27. Antiviral activity of nitazoxanide against pseudorabies virus infection in vitro - Frontiers, accessed March 19, 2026, https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1623545/full
28. Mechanism of action revealed for remdesivir, potential coronavirus drug, accessed March 19, 2026, https://www.drugtargetreview.com/news/56798/mechanism-of-action-revealed-for-remdesivir-potential-coronavirus-drug/
29. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency - PMC, accessed March 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7242698/
30. Preparing for the next viral threat with broad-spectrum antivirals - JCI, accessed March 19, 2026, https://www.jci.org/articles/view/170236
31. Molnupiravir: Mechanism of action, clinical, and translational science - PMC, accessed March 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10851176/
32. The triple combination of Remdesivir (GS-441524), Molnupiravir and ..., accessed March 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11560660/
33. Molnupiravir and Its Antiviral Activity Against COVID-19 - Frontiers, accessed March 19, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.855496/full
34. Atea Pharmaceuticals (NASDAQ: AVIR) outlines late-stage HCV Phase 3 plans - Stock Titan, accessed March 19, 2026, https://www.stocktitan.net/sec-filings/AVIR/10-k-atea-pharmaceuticals-inc-files-annual-report-6deb49bb02a0.html
35. Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

and Provides Business Update - Barchart.com, accessed March 19, 2026, https://www.barchart.com/story/news/593402/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update
36. Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss, accessed March 19, 2026, https://www.investing.com/news/transcripts/earnings-call-transcript-atea-pharmaceuticals-q4-2025-sees-stock-rise-despite-eps-miss-93CH-4545619
37. Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha, accessed March 19, 2026, https://seekingalpha.com/article/4860214-atea-pharmaceuticals-inc-avir-presents-at-44th-annual-j-p-morgan-healthcare-conference
38. AU2006313701B2 - Novel pyridopyrazines and their use as modulators of kinases - Google Patents, accessed March 19, 2026, https://patents.google.com/patent/AU2006313701B2/en
39. AU2006313701A1 - Novel pyridopyrazines and their use as modulators of kinases - Google Patents, accessed March 19, 2026, https://patents.google.com/patent/AU2006313701A1/en
40. NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - BioSpace, accessed March 19, 2026, https://www.biospace.com/press-releases/nanoviricides-dual-track-clinical-strategy-explained-by-a-research-report-broad-spectrum-antiviral-nv-387-at-phase-ii-clinical-trial-stage-for-mpox-and-also-for-acute-respiratory-infections-of-all-viruses
41. Model Medicines to Present Data on Two Drug Candidates at BIOCOM Global Partnering Conference 2026 - BioSpace, accessed March 19, 2026, https://www.biospace.com/press-releases/model-medicines-to-present-data-on-two-drug-candidates-at-biocom-global-partnering-conference-2026
42. Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus - PR Newswire, accessed March 19, 2026, https://www.prnewswire.com/news-releases/hyundai-bioscience-confirms-entry-into-us-fda-phase-2-trials-for-broad-spectrum-antiviral-xafty-following-2026-biotech-showcase-consensus-302661862.html
43. Host Directed Therapeutic Strategies to Combat Infection and Reduce Emergence of Drug Resistance Conference, accessed March 19, 2026, https://fusion-conferences.com/conference/53
44. Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome - Frontiers, accessed March 19, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1730089/full
45. Comprehensive Identification and Mechanistic Evaluation of Novel DHODH Inhibitors as Potent Broad-Spectrum Antiviral Agents - MDPI, accessed March 19, 2026, https://www.mdpi.com/1424-8247/18/9/1416

46. PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT - Genfit, accessed March 19, 2026, https://www.genfit.com/wp-content/uploads/2026/01/ntz-ddw-2023.pdf
47. TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection - PubMed, accessed March 19, 2026, https://pubmed.ncbi.nlm.nih.gov/41612887/
48. Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection - MDPI, accessed March 19, 2026, https://www.mdpi.com/2076-2607/13/5/1040